Literature DB >> 22483674

A varying patient safety profile between black and nonblack adults with decreased estimated GFR.

Clarissa J Diamantidis1, Stephen L Seliger, Min Zhan, Loreen Walker, Gail B Rattinger, Van Doren Hsu, Jeffrey C Fink.   

Abstract

BACKGROUND: Chronic kidney disease is a high-risk condition for a variety of adverse safety events, yet little is known about differential rates of safety events across racial groups with decreased kidney function. We sought to examine the incidence of an array of disease-specific adverse safety events in black versus nonblack patients with decreased estimated glomerular filtration rate (eGFR). STUDY
DESIGN: Retrospective observational study of a national US Veterans Affairs cohort. SETTINGS &amp; PARTICIPANTS: Veterans with eGFR <60 mL/min/1.73 m(2) and one or more hospitalization during federal fiscal year 2005 (n = 70,154). PREDICTOR: Self-reported race/ethnicity dichotomized as black or nonblack. OUTCOMES: Hospital discharge coding for Agency for Healthcare Research and Quality (AHRQ) patient safety indicators (PSIs), laboratory records for detection of hyperkalemia and hypoglycemia, and pharmacy records to determine dosing of 4 selected medications. MEASUREMENTS: Relationship between race and disease-specific patient safety events.
RESULTS: Black veterans were more likely than nonblack veterans to experience one type of safety event (33% vs 32%, respectively) and multiple types of safety events (32% vs 23%, respectively; both P < 0.001). After adjustment, black veterans were 11% and 36% more likely to have at least one episode of hyperkalemia and hypoglycemia, respectively, than nonblack veterans, but were 14% less likely to experience a medication error (all P < 0.001). There was no association between the occurrence of AHRQ PSIs and race after adjustment. LIMITATIONS: Use of administrative data has a risk of imprecision in coding; Veterans Affairs cohort may limit generalizability.
CONCLUSIONS: Black veterans with decreased eGFR are more likely to experience a broad array of safety events than nonblacks with decreased eGFR, with a preponderance of metabolic disturbances rather than medication errors or AHRQ PSIs. The differential safety phenotype in blacks versus nonblacks may have implications for preventive strategies to improve patient safety in an integrated health care system.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22483674     DOI: 10.1053/j.ajkd.2012.01.023

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.

Authors:  Kailin L Hsu; Jeffrey C Fink; Jennifer S Ginsberg; Marni Yoffe; Min Zhan; Wanda Fink; Corinne M Woods; Clarissa J Diamantidis
Journal:  Am J Kidney Dis       Date:  2015-05-13       Impact factor: 8.860

Review 2.  Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature.

Authors:  Avi Baehr; Juliet C Peña; Dale J Hu
Journal:  J Racial Ethn Health Disparities       Date:  2015-03-24

3.  Patient-reported and actionable safety events in CKD.

Authors:  Jennifer S Ginsberg; Min Zhan; Clarissa J Diamantidis; Corinne Woods; Jingjing Chen; Jeffrey C Fink
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

4.  Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKD.

Authors:  Clarissa J Diamantidis; Jennifer S Ginsberg; Marni Yoffe; Lisa Lucas; Divya Prakash; Saurabh Aggarwal; Wanda Fink; Stefan Becker; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-28       Impact factor: 8.237

5.  The urine microRNA profile may help monitor post-transplant renal graft function.

Authors:  Daniel G Maluf; Catherine I Dumur; Jihee L Suh; Mariano J Scian; Anne L King; Helen Cathro; Jae K Lee; Ricardo C Gehrau; Kenneth L Brayman; Lorenzo Gallon; Valeria R Mas
Journal:  Kidney Int       Date:  2013-09-11       Impact factor: 10.612

6.  Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance.

Authors:  Clarissa J Diamantidis; Sarah L Hale; Virginia Wang; Valerie A Smith; Sarah Hudson Scholle; Matthew L Maciejewski
Journal:  BMC Nephrol       Date:  2019-09-14       Impact factor: 2.388

7.  Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study.

Authors:  Joshua Z Willey; Yeseon Park Moon; S Ali Husain; Mitchell S V Elkind; Ralph L Sacco; Myles Wolf; Ken Cheung; Clinton B Wright; Sumit Mohan
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.